ArticleJHLT open2026
Infections following temporary mechanical circulatory support in cardiogenic shock: Incidence, associations, and outcomes.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infection complicates temporary mechanical circulatory support (tMCS) in cardiogenic shock (CS), but the contributions of device, severity, and timing remain unclear. Methods: Adults with CS supported by Impella, venoarterial extracorporeal membrane oxygenation (VA-ECMO), or both (ECPELLA) at a quaternary center (2021-2025) were studied retrospectively. Infection required clinician diagnosis, positive culture, and ≥5 days of targeted therapy. Cause-specific Cox and Fine-Gray competing-risks models assessed infection and a separate Cox model assessed 60-day mortality with infection as a time-varying covariate. Results: Among 297 patients, 111 (37.4%) developed a post-tMCS infection. Most first infections (75.7%) occurred within 14 days, with week-1 incidence over twice the average. Infected patients had longer hospital stays (35 vs 19 days, Conclusions: Infection affected more than one-third of CS-tMCS patients, with peak risk in the first week. VA-ECMO support carried higher infection risk. Sixty-day mortality tracked older age and lactate at tMCS placement, but not device type. Infection was not associated with increased mortality but was associated with longer hospitalization and worse discharge disposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.